Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
HOUSTON , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy volunteers. As previously announced, the trial met the safety and tolerability
View HTML
Toggle Summary Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates
- Merger completed; now operating as Aravive, Inc. (Nasdaq:ARAV), a clinical-stage biopharmaceutical company advancing innovative oncology therapeutics                - FDA Fast Track designation granted for lead candidate, AVB-S6-500                - Initiation of the Phase 1b portion of a Phase
View HTML
Toggle Summary Aravive Biologics and Versartis Complete Merger
The combined company, Aravive, Inc. , to trade on Nasdaq under ticker symbol “ARAV” beginning October 16, 2018 , concurrent with a 1-for-6 reverse split of common shares HOUSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Aravive Biologics, Inc. and Versartis, Inc.
View HTML
Toggle Summary U.S. FDA Grants Fast Track Designation to Aravive Biologics’ AVB-S6-500
HOUSTON, TEXAS (August 20, 2018): Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.   “Gaining Fast Track Designation is an important
View HTML
Toggle Summary Aravive Biologics Completes Phase 1 Trial of Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500
Aravive Biologics, Inc. announced today that the company has completed both the single ascending dose and repeat dose portions of its Phase 1 study of AVB-S6-500 in healthy volunteers. The study met the safety and tolerability endpoints for the trial.
View HTML
Toggle Summary Versartis Aravive Proposed Merger Presentation
Versartis enters into merger agreement with Aravive Biologics to form a clinical-stage biopharmaceutical company advancing innovative oncology therapeutics. View presentation >
View HTML
Toggle Summary Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics
Versartis, Inc. (NASDAQ:VSAR), and Aravive Biologics, Inc., today jointly announced that they have entered into a definitive agreement under which Aravive will merge with a wholly owned subsidiary of Versartis in an all-stock transaction. The transaction will result in a clinical stage,
View HTML
Toggle Summary Aravive Biologics Achieves Proof-of-Mechanism for Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500, in Ongoing Phase 1 Trial
Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase I study (32 subjects). The objective of this study is to evaluate the safety,
View HTML
Toggle Summary Aravive Biologics Expands Scientific and Clinical Advisory Team
Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced two new appointments to the company’s scientific advisory board. Kimberly L. Blackwell, M.D., Vice President, Early Phase Oncology and
View HTML
Toggle Summary Aravive Biologics Initiates Phase 1 Study of Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500
Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced the initiation of a Phase 1 clinical trial of AVB-S6-500 (previously referred to as Aravive-S6).  The study is being conducted in the United States
View HTML